In the two studies that measured and found indications for MMPs breast cancer outcomes; the first explored the effect of a novel non-steroidal anti-inflammatory drug (NSAID), β-D-Mannuronic acid (M2000), on gene expression in breast cancer patients, where researchers found that NSAID use reduced the levels of MMP-2 and MMP-9 gene expression (75). This evidence concerns the gene MMP2 and breast carcinoma.